DAHLIAS study - Nipocalimab in Sjögren's Disease
Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.
Read Article
Sjogren’s disease: two drugs with positive trials Sjogren’s disease: two drugs with positive trials
After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost! At #ACR25, not one but two drugs presented their efficacy https://t.co/tGwUrLMZEI
Dr. John Cush @RheumNow( View Tweet )
Sjögren's disease RCTs: Has the Long Drought Ended?
At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
https://t.co/nNNx5sXzCz https://t.co/r9VBgyYgOC
Dr. John Cush @RheumNow( View Tweet )
20-40% of Autoimmune hepatitis (AIH) is associated with other autoimmune diseases - lead by autoimmune thyroiditis, type 1 DM, ulcerative colitis, Crohn disease, & celiac (but less so for RA, PBC, SLE, Sjögren syndrome, vitiligo). AIH Dx Abs include ANA, ASMA, LKM1. https://t.co/I3ZPHiRgqZ
Dr. John Cush @RheumNow( View Tweet )
Sjogren’s disease: two drugs with positive trials Sjogren’s disease: two drugs with positive trials
After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost! At #ACR25, not one but two drugs presented their efficacy https://t.co/kTTdZnVUtj
Dr. John Cush @RheumNow( View Tweet )
Ianalumab Shows Phase 3 Success in Sjögren’s: Is It Clinically Meaningful?
On the final day of ACR25, late-breaking abstract #24 drew particular attention, presenting results from the first positive Phase 3 trials of a potential systemic treatment for a disease that has long lacked one.
Read Article
ACR 2025 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
Read Article
NEPTUNUS: Ianalumab in Sjogren's https://t.co/K9Xm51Kb5X
Finally good news in Sjogrens disease.
@RheumNow
#ACR25
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
#ACR25 Please find my blog on update and progress of clinical trials in #Sjogren #SjD @RheumNow
https://t.co/u8pxZ5FeBX https://t.co/KAnRo3Zqnz
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
What to use in future for active #Sjogren's #SjD
B cell depletion, signal attenuation
Ianalumab 2+ phase3 RCTs
Telitacept +RCT
Nipocalimab FcRn +Ph2
Dazodalibep CD40L +Ph2
+RCTs
HCQ+Lef
Rituximab
?BTKi
#ACR25 @ACRheum @RheumNow
abst#LB24, LB11
Janet Pope @Janetbirdope( View Tweet )
Sjogren’s disease: two drugs with positive trials
After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost! At this year’s ACR25 Convergence Conference in Chicago, not one but two drugs presented their efficacy and safety data in patients with moderate to severe disease
Read Article
#Ianalumab decreases disease activity in active #Sjögren's #disease
2 phase3 DB #RCT added to #SoC in primary #SjD
>90% #Ro+
+#ESSDAI in monthly sc dosing vs placebo,
Many 2ndary outcomes improved, safe
LB#24 #ACR25 @ACRheum @RheumNow
#ACRBest https://t.co/Z4ooUg7Nos
Links:
Janet Pope @Janetbirdope( View Tweet )
#ACR25 Please find my video summary on the Phase 3 RCTs results of Ianalumab in moderate to severe disease activity in #Sjogren Disease presented during Late Breaking Abstract session Abstr#LB24 #SjD @RheumNow
https://t.co/ngCAglwAO0 https://t.co/PaUYsxhBKS
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo.
ΔESSDAI at 48wk: Ianalumab QM > PBO, statistically significant
But ΔESSDAI ≈ 0.5–1 pt (vs PBO) below MCII (≥ 3)
Promising biology, modest clinical gain
#ACR25 @RheumNow LB24 https://t.co/8y580ch9iJ
Jiha Lee @JihaRheum( View Tweet )
Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy?
Ianalumab (BAFF inh) ph3 NEPTUNUS-1/2
Very decent on primary (ESSDAI) & we will see this
Salivary flow only improved when some at baseline
#ACR25 LB24 @RheumNow https://t.co/uGwKdN3Dsh
Links:
David Liew @drdavidliew( View Tweet )
#ACR25 Abstr#LB24 The first Phase 3 RCTs in #Sjogren meeting primary endpoint! In moderate-to-severe activity, both RCTs = improvement in ESSDAI vs PBO (pooled effect -1.2 reduction). High PBO rate. PGA, PaGA & Stimulated Salivary Flow) improved. No diff in ESSPRI/FACIT @RheumNow https://t.co/rAs6NeXDIn
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Grader-Beck et al. Ianalumab in Sjogren's disease. NEPTUNUS 1 and 2 studies. 779 patients. Met primary endpoint ESSDAI. Big placebo effect also. Patient and physician global also improved. @RheumNow #ACR25 Abstr#LB24 https://t.co/klhxXW4Jfh
Richard Conway @RichardPAConway( View Tweet )
ACR25 Best Abstracts - Day 3
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025. Below are several of the best abstracts from Day 3, as chosen by our outstanding
Read Article
What's new in sjogren's?
Promising phase III data of telitacicept (dual BLyS + APRIL neutralization)
Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose
Similar rates of adverse events
@RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH
Brian Jaros, MD @Dr_Brian_MD( View Tweet )
Sjögren’s, decoded by Ab -->ESSDAI domains:
• anti-SSA → glandular
• anti-Ro52 / SCL70 → biologic activity
• anti-nucleosome → pulmonary
• anti-histone → pulmonary + cutaneous
Distinct serologic–ESSDAI patterns may guide monitoring and management
@RheumNow #ACR25 A#2295
Jiha Lee @JihaRheum( View Tweet )
#ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too!
Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest https://t.co/LXxpBZPCtF
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#ClinicalPearl
Pts w #SpA ex #PsA May have
👇
#sicca #dry #eyes #dry mouth
Inflamed gallbladder without calculi
👇
Can be associated w #autoimmune disease
#POTS can be initial presentation of #SjD
IgA vasculitis—May have #cancer
#Secrets & #Pearls #ACR25 @RheumNow @ACRheum https://t.co/4SAqVYjnrD
Janet Pope @Janetbirdope( View Tweet )
Who talks to their neighbour?
+SSA / Ro talk differently to nearby cells in #SjD #salivary #glands vs NEG Ro SjD
Ro52 acts differently than Ro60
?implications for Rx response? 🤷♀️
#ACR25 @RheumNow @ACRheum #Sjogren’s
Abst#1684
#ACRBest!
Elegant work from Sara McCoy https://t.co/UWUKAxi0UW
Links:
Janet Pope @Janetbirdope( View Tweet )
#ACR25 Abstr#1401 Sjogren’s #SjD is definitely not a benign disease! Real world study using US database showed high disease burden within 12 mths of diagnosis (i.e. healthcare resource use). GC use was high (~50%). Better therapy is needed to improve outcomes @RheumNow https://t.co/MI3vQ5LByr
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Need better lymphoma biomarkers in Sjögren’s?
APRIL joins BAFF as a promising candidate—high APRIL levels linked to ↑ B-cell activation, disease activity & future lymphoma.
Easily measurable, potentially targetable.
@RheumNow #ACR25 Abstract #1683
Jiha Lee @JihaRheum( View Tweet )
